Same-arm booster shots trigger a stronger early immune response than shots given in the opposite arm, leading to higher ...

Pfizer Inc. and BioNTech SE failed to knock out any of Alnylam Pharmaceuticals Inc.’s patents in a case over the partners’ Covid-19 vaccines, as a federal judge said he made no findings that would let ...

Research teams across Canada are now building on homegrown innovation to expand the potential of RNA vaccines beyond ...

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an ...

Novavax's protein-only vaccine is once again expected to move from emergency approval to full approval status following a pause.

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Here are eight possible indicators of how health secretary Robert F. Kennedy Jr. may handle U.S. vaccine policy in coming ...

The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.

Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research ...

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.